Lexicon Pharmaceuticals, Inc. LXRX
We take great care to ensure that the data presented and summarized in this overview for LEXICON PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LXRX
View all-
Artal Group S.A. Luxembourg, N4118MShares$202 Million15.21% of portfolio
-
Black Rock Inc. New York, NY7.69MShares$13.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.4MShares$11 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$6.09 Million0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA2.39MShares$4.11 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD2.38MShares$4.1 Million0.4% of portfolio
-
State Street Corp Boston, MA1.99MShares$3.42 Million0.0% of portfolio
-
Pinnacle Associates LTD1.75MShares$3.01 Million0.07% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$2.9 Million0.12% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.42MShares$2.44 Million0.0% of portfolio
Latest Institutional Activity in LXRX
Top Purchases
Top Sells
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Transactions at LXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
Artal International S.C.A. |
BUY
Exercise of conversion of derivative security
|
Indirect |
57,546,100
+29.7%
|
-
|
|
Apr 28
2024
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+4.59%
|
-
|
|
Apr 28
2024
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+14.24%
|
-
|
|
Apr 28
2024
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+3.13%
|
-
|
|
Apr 28
2024
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+8.39%
|
-
|
|
Apr 28
2024
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+0.59%
|
-
|
|
Apr 28
2024
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+14.24%
|
-
|
|
Mar 13
2024
|
Artal International S.C.A. |
BUY
Grant, award, or other acquisition
|
Indirect |
1,150,922
+50.0%
|
$124,299,576
$108.5 P/Share
|
|
Feb 28
2024
|
Wendy Mc Dermott VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
22,425
-29.85%
|
$44,850
$2.62 P/Share
|
|
Feb 28
2024
|
Wendy Mc Dermott VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
46,641
+27.74%
|
-
|
|
Feb 28
2024
|
Jeffrey L Wade President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,691
-10.41%
|
$75,382
$2.62 P/Share
|
|
Feb 28
2024
|
Jeffrey L Wade President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
97,564
+8.83%
|
-
|
|
Feb 28
2024
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
11,793
-19.79%
|
$23,586
$2.62 P/Share
|
|
Feb 28
2024
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
29,243
+16.07%
|
-
|
|
Feb 28
2024
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
25,604
-12.61%
|
$51,208
$2.62 P/Share
|
|
Feb 28
2024
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
68,303
+11.07%
|
-
|
|
Feb 28
2024
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
24,408
-8.71%
|
$48,816
$2.62 P/Share
|
|
Feb 28
2024
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
67,546
+7.94%
|
-
|
|
Feb 28
2024
|
Lonnel Coats Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
61,371
-5.29%
|
$122,742
$2.62 P/Share
|
|
Feb 28
2024
|
Lonnel Coats Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
245,080
+6.96%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 58.3M shares |
|---|---|
| Open market or private purchase | 29M shares |
| Grant, award, or other acquisition | 1.15M shares |
| Payment of exercise price or tax liability | 239K shares |
|---|